Untitled

Abstract

The present study is undertaken with an aim to improve the dissolution profile and availability of a poorly soluble drug, Lornoxicam, through the development of liquisolid tablets. Liquisolid compacts were prepared by employing PEG 400, Avicel PH 112, and Aerosil 200 as solvent, carrier and coating materials, respectively. The flow properties of the drug improved significantly after formulating it into the liquisolid compacts. The post-compressional parameters of prepared tablets revealed the uniformity and maintenance of standards within the different batches. In-vitro drug release studies showed significant improvement in the dissolution of lornoxicam in its liquisolid form compared to a commercial product. The effect of formulation parameters, such as drug concentration and carrier to coat ratio, on enhancing drug dissolution, was also explored. FT-IR, DSC and XRD techniques were employed for the physical characterization of the drug in the liquisolid systems. The drug release from the optimized liquisolid compacts (F8) followed first-order release kinetics. INTRODUCTION: Solubility is one of the important parameters to achieve the desired concentration of drug in systemic circulation for achieving required pharmacological response. Poorly water-soluble drugs often require high doses in order to reach the therapeutic plasma concentrations after oral administration. Most of the drugs are either weakly acidic or weakly basic, having poor aqueous solubility, thus producing major problems with formulation development of new chemical entities. Hence, a significant number of new and possibly beneficial chemical entities do not have suitable pharmaceutical dosage form because of their poor solubility and poor dissolution rate 1, 2 .